Skip to main navigation

Investors
News
- News Releases
- News and Mentions
Presentations & Events
- Presentations
- Events
Stock Performance
- Stock Information
- Analyst Coverage
Financials & Filings
- SEC Filings
- Quarterly Results
Corporate Governance
Resources

News Releases

Year

Sep 20 / 23

Belite Bio Announces EMA Submission for Tinlarebant Phase 3 GA Clinical Trial in the EU

Sep 01 / 23

Belite Bio Announces MHRA Submission for Tinlarebant Phase 3 GA Clinical Trial in United Kingdom

Aug 08 / 23

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 04 / 23

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

Aug 04 / 23

Belite Bio Receives Approval to Initiate Tinlarebant (LBS-008) Phase 3 Clinical Trial for GA in Australia

Jul 27 / 23

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

Jul 24 / 23

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

Jul 17 / 23

Belite Bio Receives Approval to Initiate Tinlarebant (LBS-008) Phase 3 Clinical Trial for GA in Taiwan

Jul 06 / 23

Belite Bio Announces TFDA Submission for Tinlarebant Phase 3 GA Clinical Trial in Taiwan

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 9 of 24

Belite Bio™ Inc
12750 High Bluff Drive Suite 475,
San Diego CA, 92130 USA

Join our mailing list.

Sign up to receive important updates and news from Belite Bio